Immunex Receives FDA Clearance for Etoposide Chemotherapy Agent
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Immunex Receives FDA Clearance for Etoposide Chemotherapy Agent

SEATTLE, March 15, 1996 -- Immunex Corporation (Nasdaq: IMNX) announced today that it received marketing clearance from the U.S. Food and Drug Administration (FDA) for etoposide injection (also known as VP-16), a generic cancer chemotherapy agent indicated for the treatment of refractory testicular tumors and small cell lung cancer.

"Etoposide advances our strategy of providing our customers with a broad range of oncology products -- including tools for the diagnosis, treatment, and supportive care in cancer treatment," said Michael Kranda, Immunex president and chief operating officer.

Etoposide expands the spectrum of oncology products available from Immunex, which includes the Biomira Truquant(R) BR(TM) (a test for the detection of recurrent breast cancer), Novantrone(R) (mitoxantrone for injection concentrate), Thioplex(R) (thiotepa for injection), leucovorin calcium, methotrexate sodium, and Leukine(R) (sargramostim), a yeast-derived granulocyte-macrophage colony stimulating factor.

Etoposide is a semi-synthetic derivative of a plant-derived toxin that inhibits the protein synthesis and DNA replication of tumor cells. The generic drug was co-developed by Immunexand Wyeth-Ayerst Research and is available in 100 and 250 milligram vials. The 250 milligram vial is available exclusively from Immunex.

Immunexis a biopharmaceutical company dedicated to developing immune system science to protect human health.

American Home Products Company (NYSE: AHP) owns a majority interest in Immunex. AHP is one of the world's largest research-based pharmaceutical and health care products companies and is a leading developer, manufacturer and marketer of prescription drugs and over-the-counter medications. It is also a leader in vaccines, generic pharmaceuticals, biotechnology, agricultural products, animal health care, medical devices and food products.

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities